Treace Medical Concepts, Inc. · NASDAQ:TMCI
Treace Medical Concepts — Investor Presentation (January 2025)
22 slides from Treace Medical Concepts's investor presentation, Jan 13, 2025
Slide 1: Investor Presentation January 2025: On solid footing for sustained growth
Investor Presentation January 2025 On solid footing for sustained growth 1 Exhibit 99.2
Slide 2: Forward-looking statements
This presentation may include forward- looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, strategy and plans, industry environment, potential growth oppor
Slide 3: Non-GAAP Financial Measures
Non-GAAP Financial Measures 3 To supplement the financial results presented in accordance with GAAP, this presentation presents Adjusted EBITDA, which the Company defines as net loss before depreciation and amortization expense, interest income, interest expense, taxes, share-based compensation expe
Slide 4: Treace Medical Concepts, Inc.: The Leader in 3D Bunion Correction
Treace Medical Concepts, Inc. Medical Device company focused on the surgical treatment of bunions and related deformities Industry’s Only Bunion Focused Direct Sales Team Market Leading Technology protected by 71 US Patents and 81 US Pending Patents Strong Growth FY 2024 preliminary revenue of $209.
Slide 5: A large, underserved $5B+ U.S. market opportunity
Emily Lapiplasty® patient $5B+ U.S. market opportunity A LARGE, underserved Bunions affect ~1 in 4 U.S. adults¹, a population of 65 million 10,000+ U.S. bunion surgeons 450k annual surgical procedures2: $2.3B current market 650k more in need of surgery: $3.3B market 5 Nix S, et al. J Foot Ankle Res
Slide 6: Bunions: 3-Plane Deformities
Transverse Plane Sagittal Plane Frontal Plane Bunions: 3-Plane Deformities 6 An unstable joint in the middle of the foot allows the metatarsal bone to shift outward… Bunion (bump) presents here Unstable joint is here In nearly 90% of bunions, the metatarsal bone is rotated in the frontal plane1 Cre
Slide 7: Traditional 2D Surgical Approaches Have Significant Shortcomings
Traditional 2D Surgical Approaches Have Significant Shortcomings 7 Relatively straightforward procedure Doesn’t address the unstable joint Increased recurrence risk1 2D OSTEOTOMY (~70% of cases) Cuts the metatarsal bone and shifts the bump inward 2D LAPIDUS FUSION (~30% of cases) Realigns the entire
Slide 8: Lapiplasty 3D Bunion Correction
Lapiplasty® 3D Bunion Correction® Our patented 3D solution: 8 Correct. Make correction before you cut Fixate. Apply multiplanar fixation for robust stability Cut. Perform precision cuts with confidence Compress. Achieve controlled compression of joint surfaces Treace has democratized a 3D Lapidus bu
Slide 9: Compelling outcomes supported by differentiated clinical data
Patient Reported Outcomes, Mean (95% Cl) Visit MOxFQ and VAS Pain Scores Over Time Compelling outcomes supported by differentiated clinical data EARLY WEIGHT BEARING in 8.4 days (avg)1,2 (1) Interim ALIGN3D™ study report, AOFAS 2024; HVA >20 degrees; 0.7% of patients (1 of 151 patients) at 24 months
Slide 10: Expanding comprehensive bunion portfolio
Expanding comprehensive bunion portfolio 10 new product launches in 2H 2024 & 2025 Addressing all bunion types with new platforms and technologies Poised for acceleration 10
Slide 11: US Bunion Opportunity - Treace Flagship Platforms
US Bunion Opportunity - Treace Flagship Platforms Mild to Moderate Moderate to Severe W/Midfoot Deformity W / Arthritic Great Toe Joint Comprehensively Addressing All Bunion Classes 11 Expanding our reach with best-in-class bunion technologies
Slide 12: US Bunion Opportunity - New 3D Procedures
US Bunion Opportunity - Treace Flagship Platforms Mild to Moderate Bunions Mild to Severe Bunions W/Midfoot Deformity W/Arthritic Great Toe Joint Expanding Our Leadership Position New 3D Procedures to Accelerate Bunion Market Penetration Micro-Lapiplasty® Nanoplasty™ Percuplasty™ Mini-Adductoplasty™
Slide 13: Intelligent Pre-Op Planning: IntelliGuide PSI
Intelligent Pre-Op Planning Comprehensive visualization of patient’s unique deformity before surgery Patient-Specific 3D Correction First and only patient-specific cut guides with built-in personalized mid-foot correction in the US Streamlined Workflow Fewer steps and less instrumentation to drive O
Slide 14: Enabling Platform Technology: SpeedPlate Rapid Compression Implants
14 Enabling Platform Technology SpeedPlate™ Rapid Compression Implants SpeedPlate™ MicroQuad NEW SpeedPlate™ 23X20 Q3 2024 Encompasses locking plate and screw construct. For complete information see ASTM F136-13, Standard Specification for Wrought Titanium-6Aluminum-4Vanadium ELI (Extra Low Intersti
Slide 15: A unique, highly scalable model
High margin, sterile implant kits Low cost, reusable instruments A unique, highly scalable model Margin from one procedure pays for our instrument tray 15 ~130 sellable SKUs facilitate supply chain and inventory management with ~80% gross margin 15 Jim Lapiplasty® patient
Slide 16: Go-to-Market Strategy
16 Go-to-Market Strategy Comprehensive introductory and advanced events with experienced surgeon faculty Hands-on training events Outreach multi-platforms Educate Lapiplasty.com Search for a doctor Schedule an appointment ~82% Direct revenue mix ~227 Sales reps1 ~329 Field fleet1 Industry’s only dir
Slide 17: Introducing Multiple New Bunion-Focused Technologies to Our Growing Base of Customers
Introducing Multiple New Bunion-Focused Technologies to Our Growing Base of Customers (1) 5-year CAGR reflects fiscal years 2019 through 2024 Active Surgeons perform at least one Lapiplasty® procedure in the trailing twelve months Average revenue per surgeon is actual/estimated full year revenue div
Slide 18: Market-capturing momentum: Revenue and penetration
Segment Penetration2 Market-capturing momentum A Step Ahead $57.4 2020 $141.8 2022 $94.4 2021 ~$209.2 2024E Revenue¹ ($Millions) 18 Revenue for 2024 is preliminary, subject to change, and represents the midpoint of the expected revenue range of $209.0 million to $209.4 million for full-year 2024 Lap
Slide 19: Meaningful leverage opportunities to drive profitability
Meaningful leverage opportunities to drive profitability Continued focus on operating expense leverage & management Scalability of business Technology-enabled efficiencies Improved 45% compared to Q3’ 23 The Company defines Non-GAAP adjusted EBITDA as net loss before depreciation and amortization ex
Slide 20: Solid footing, setting the pace
Solid footing, setting the pace Now a comprehensive bunion solutions company with multiple new technologies Positioned to deliver continued, strong revenue growth in 2025 and beyond Expecting Modest Positive Adj. EBITDA for full-year 2025 and free cash flow breakeven in 2026 The Leader in the most e
Slide 21: Treace: A Step Ahead
TREAC= A Step Ahead.
Slide 22: GAAP to Non-GAAP Reconciliations
GAAP to Non-GAAP Reconciliations 22
Treace Medical Concepts — Investor Presentation (January 2025) on 6ix